1. Current status and future prospectives of technology transfer at the Croatian Ruđer Bošković Institute Danica Ramljak, D.V.M., Ph.D.

2. I NSTITUTE TODAY 20 000 2 area

3. IRB OVERVIEW BY BRANCHES

4. 198YOUNG RESEARCHERS 34YOUNG RESEARCHERS WITH PhD 118 SENIOR RESEARCH ASSOCIATES 95 RESEARCH ASSOCIATES 97 SENIOR RESEARCHERS TOTAL = 867 EMPLOYEES 542 RESEARCH STAFF (344 WITH PhD) + 325 SUPPORT AND TECHNICAL STAFF > 200 znanstvenih novaka

5. MISSION High quality basic research Strong involvement in higher education Leading contribution to the growth of the national economyVISION EU Centre of scientific excellence Delivering knowledge and values to industry, government and academic institutions

6. RBI scientists - 6% of the total no. of scientists in Croatia  32 % of all Croatian articles cited in Current Content SCIENTIFIC PUBLICATIONS 200420052006200720082009 364389356408406440 CC Papers: 2004 - 2009

7. How can the best scientific institute in Croatia contribute to development of the TT and National Innovation System?

8. THERE IS NO EFFICIENT TT and INNOVATION SYSTEM WITHOUT: Strong basic research Strong applied research Strong cooperation between scientific community, academia and industry Strong education system Strong leadership STRONG NATIONAL GOVERNMENT COMMITMENTSTRONG NATIONAL GOVERNMENT COMMITMENT

9. INNOVATIONS IDEAS FUNDING IPAND PATENTS IP AND PATENTS TECHNOLOGY TRANSFER

10. Intellectual Property and Commercialization  RBI’s Agency founded in 2007  specialized in commercialization of innovations and technology transfer  links science and technology with economy and industry. Portfolio: more than 80 innovations and scientific projects in various fields with commercial potential but primarily in chemistry, medicine, biology, physics and informatics  7 employees,  more than 80 projects (32 outside RBI),  32 patent applications  7 license agreements, 1 patent granted and 5 spin-offs

11. Spin off companies Ru đ er Innovations Commercialization of innovations and technology transfer Ru đ er Medikol Cyclotrone Development and production of radionuclides Ru đ er Medikol Diagnostics Breast and other genetic hereditary diagnostics Initium Futuri Innovative ICT technologies BioZyne (in formation) Biotech company for R&D in the life sciences (cancer drugs)

13. 13 IF IN NUMBERS Year20072008Sep 2009 Expected in 2009 20102011 Staff455566 Projects345567 Licences, business contr. 012246 Revenue (EUR)026631,7238125,56 cca. 72000 100150 Investment: 154kEUR Ownership: RI 51%, inventors (4) 49% Profit sharing: RI:51%, inventors (4) 49%

14. IF PROJECT PORTFOLIO 14 SmartECG - Mobile Heartwork analysis and alarming system Vergilius – Navigation for visually impaired Eduforia – eLearning and collaboration software ePortfelj – Web 2.0 personal investment portfolio manager Custom software and consulting services – one big BPR (Business Process Reengineering) project in progress

15. 15 RMD IN NUMBERS Year2008Sep 2009 Staff11 Projects/diagnoses?02 Revenue (k EUR)02 Costs (k EUR)199 Investment: 50kEUR Ownership: RI 50%, Medikol 50% Profit sharing: RI:80%,Medikol 20%

16. Do research and TT at IRB need improvement ? YES !

17. RBI  EU CENTRE OF EXCELLENCE VISIBILITY INTERNATIONAL COOPERATION EDUCATION PATENTS, FUNDRAISING IMPROVE INTEGRATION IMPROVE RESEARCH INFRASTRUCTURE IMPACT PAPERS INCREASE #INTERNATIONA L PROJECTS COOPERATION WITH INDUSTRY

19. VISIT TO WEIZMANN INSTITUTE

20. THANK YOU !